ArticleClinical rheumatology2026
The relationship between hematological indices of systemic inflammation and disease activity in patients with rheumatoid arthritis: a retrospective cross-sectional study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveMonitoring rheumatoid arthritis (RA) disease activity is crucial for treatment optimization. Hematological indices (SII, SIRI, NLR, PLR, MLR) show promise as systemic inflammation biomarkers. This study assessed their correlation with RA disease activity versus healthy controls.
methodsThis retrospective cross-sectional study included 204 ACR/EULAR-classified RA patients and 216 age-/sex-matched controls. Complete blood counts enabled calculation of SII (neutrophils × platelets/lymphocytes), SIRI (neutrophils × monocytes/lymphocytes), NLR, PLR, and MLR. Disease activity was measured via DAS-28-ESR.
resultsRA patients (96.2% female, age 50.9 ± 12.4 years) demonstrated significantly elevated indices versus controls (94.4% female, age 47.2 ± 11.9 years): SII (722.7 ± 695.2 vs. 563.1 ± 448.9; p = 0.006), SIRI (12.36 ± 9.46 vs. 10.32 ± 5.78; p = 0.009), PLR (12.10 ± 14.40 vs. 9.64 ± 9.67; p = 0.039), MLR (0.21 ± 0.19 vs. 0.17 ± 0.08; p = 0.015). Among RA patients, active disease (DAS-28 > 2.6) exhibited significantly higher SII (780.6 ± 826.1 vs. 614.4 ± 310.4; p = 0.040) than remission. ROC analysis identified SII/SIRI as strong predictors (AUC train/test: 0.946/0.898).
conclusionHematological indices were significantly higher in RA patients and associated with disease activity. SII and SIRI demonstrated superior predictive capability for active RA. Key Points • This retrospective cross-sectional study included 204 patients with rheumatoid arthritis and 216 age- and sex-matched healthy controls. • Hematological indices including SII, SIRI, NLR, PLR, and MLR were significantly higher in RA patients compared to controls. • Among these indices, SII and SIRI showed the strongest correlation with disease activity measured by DAS-28. • SII and SIRI demonstrated excellent predictive performance for distinguishing active disease from remission, suggesting their potential as simple and cost-effective biomarkers for clinical monitoring.
Indexed as
Identifiers
42252375What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.